What is HC Wainwright’s Estimate for IPSC FY2024 Earnings?

Century Therapeutics, Inc. (NASDAQ:IPSC) – Investment analysts at HC Wainwright raised their FY2024 EPS estimates for shares of Century Therapeutics in a research report issued to clients and investors on Wednesday, November 6th. HC Wainwright analyst M. Kapoor now forecasts that the company will earn ($1.66) per share for the year, up from their prior forecast of ($1.71). HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for Century Therapeutics’ current full-year earnings is ($1.80) per share.

Century Therapeutics (NASDAQ:IPSC) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.08. The company had revenue of $0.79 million for the quarter, compared to the consensus estimate of $0.47 million. Century Therapeutics had a negative net margin of 6,434.23% and a negative return on equity of 60.60%. During the same quarter last year, the firm posted ($0.55) earnings per share.

IPSC has been the topic of several other research reports. Chardan Capital dropped their price objective on shares of Century Therapeutics from $17.00 to $11.00 and set a “buy” rating on the stock in a research note on Thursday. Rodman & Renshaw started coverage on Century Therapeutics in a report on Thursday, August 8th. They set a “buy” rating and a $6.00 price target on the stock. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $11.60.

Century Therapeutics Stock Down 1.4 %

IPSC stock opened at $1.44 on Friday. The company has a market capitalization of $121.99 million, a PE ratio of -0.79 and a beta of 1.41. The stock’s 50 day moving average is $1.52 and its two-hundred day moving average is $2.23. Century Therapeutics has a 52-week low of $1.14 and a 52-week high of $5.51.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of IPSC. SG Americas Securities LLC bought a new position in shares of Century Therapeutics during the 3rd quarter worth about $27,000. Renaissance Technologies LLC increased its position in shares of Century Therapeutics by 6.1% during the 2nd quarter. Renaissance Technologies LLC now owns 165,500 shares of the company’s stock worth $422,000 after purchasing an additional 9,500 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Century Therapeutics by 141.7% in the second quarter. Dimensional Fund Advisors LP now owns 75,315 shares of the company’s stock valued at $192,000 after acquiring an additional 44,155 shares during the last quarter. Rhumbline Advisers boosted its holdings in shares of Century Therapeutics by 56.0% in the 2nd quarter. Rhumbline Advisers now owns 52,466 shares of the company’s stock worth $134,000 after acquiring an additional 18,828 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in Century Therapeutics by 110.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 149,000 shares of the company’s stock valued at $380,000 after purchasing an additional 78,088 shares in the last quarter. 50.20% of the stock is currently owned by institutional investors and hedge funds.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.